Biotechnology company Moderna, Inc. (NASDAQ: MRNA) Thursday reported a sharp decline in revenues for the second quarter of 2024.
- Second-quarter revenues decreased to $241 million from $344 million in the prior-year period
- Net loss narrowed to $1.28 billion or $3.33 per share in Q2 from $1.38 billion or $3.62 per share a year earlier
- Net product sales for the quarter were $184 million, reflecting a 37% decrease from the same period in 2023
- For fiscal 2024, the company expects total product sales to be between $3.0 billion and $3.5 billion
- Full-year cost of sales is expected to be in the range of 40-50% of product sales
- Q2 cost of sales was $115 million, including third-party royalties unutilized manufacturing capacity & wind-down costs, and inventory write-downs
- Cash, cash equivalents, and investments as of June 30, 2024, were $10.8 billion, vs. $12.2 billion as of March 31, 2024
Listen to the conference calls as they happen. Don't miss a beat! With AlphaStreet Intelligence, you can listen to live calls and interviews as they happen, so you never have to worry about missing out on important information.
Most Popular
NFLX Earnings: Netflix Q1 2025 revenue and profit beat estimates
Netflix, Inc. (NASDAQ: NFLX) on Thursday reported stronger-than-expected revenue and earnings for the first quarter of 2025, as its subscriber base continued to expand. Both revenue and the bottom line
Another tough quarter in the cards as Intel prepares for Q1 2025 earnings
Intel Corporation (NASDAQ: INTC) has been facing intense competition from rivals Nvidia in AI chips and AMD in CPUs, lately. The Semiconductor giant issued weak guidance after reporting lower revenues
What to expect when American Airlines (AAL) reports Q1 2025 earnings results
Shares of American Airlines Group (NASDAQ: AAL) stayed red on Thursday. The stock has dropped 48% over the past three months. The airline is slated to report its earnings results
